Histone deacetylase 1 and 3 inhibitors alleviate colon inflammation by inhibiting Th17 cell differentiation
Authors:
Open Access
- 15 September 2022
- journal article
- research article
- Published by Wiley in Journal of Clinical Laboratory Analysis
- Vol. 36 (10) , e24699
Abstract
Background: The etiology of inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn's disease (CD), is not completely clear, but its pathogenesis is closely related to T helper 17 (Th17) cells. Several histone deacetylase (HDAC) inhibitors have been shown to exert potent anti‐inflammatory effects and modulate Th17 cell polarization. Owing to the large variety and broad expression of HDACs, finding specific therapeutic targets for IBD is of clinical importance. Methods: The proportions of Th17 cells and interleukin (IL)‐17A produced between patients with UC and healthy volunteers were compared. The differentiation of human peripheral blood mononuclear cells (PBMCs) into Th17 cells was induced in vitro. Differentiated Th17 cells were treated with RGFP109 (RG), a selective inhibitor of HDAC1 and 3, to observe its effects on these cells. Subsequently, colitis was induced in mice and treated with RG. The proportion of Th17 cells, the severity of colitis in mice, and colon histopathology and immunohistochemistry were evaluated respectively. Results: The proportion of Th17 cells and IL‐17A production was significantly increased in patients with UC than in healthy individuals. RG inhibited the differentiation of human PBMCs into Th17 cells and reduced IL‐17A secretion in vitro. RG‐treated colitis mice had a lower Th17 ratio, mild colon inflammation, and decreased expression of HDAC1 and 3 in the colon. Conclusions: HDAC1 and 3 inhibitors can modulate the differentiation of inflammatory Th17 cells, downregulate IL‐17A levels, and exert anti‐inflammatory effects in experimental colitis mice, indicating that HDAC1 and 3 may be potential therapeutic targets for patients with IBD.Keywords
Funding Information
- National Natural Science Foundation of China (82170551)
This publication has 50 references indexed in Scilit:
- Targeting Th17 cells in autoimmune diseasesTrends in Pharmacological Sciences, 2014
- Histone deacetylase inhibitors and cell deathCellular and Molecular Life Sciences, 2014
- Erasers of Histone Acetylation: The Histone Deacetylase EnzymesCold Spring Harbor Perspectives in Biology, 2014
- Histone Deacetylase Inhibitors Modulate Interleukin 6-dependent CD4+ T Cell Polarization in Vitro and in VivoJournal of Biological Chemistry, 2014
- Innate and adaptive immunity in inflammatory bowel diseaseAutoimmunity Reviews, 2014
- Histone deacetylase 3 coordinates commensal-bacteria-dependent intestinal homeostasisNature, 2013
- RGFP109, a histone deacetylase inhibitor attenuates l-DOPA-induced dyskinesia in the MPTP-lesioned marmoset: A proof-of-concept studyParkinsonism & Related Disorders, 2013
- Requirement for the histone deacetylase Hdac3 for the inflammatory gene expression program in macrophagesProceedings of the National Academy of Sciences, 2012
- Inflammatory bowel diseaseOral Diseases, 2011
- Antibodies to interleukin 12 abrogate established experimental colitis in mice.Journal of Experimental Medicine, 1995